Long-Term Outcomes of Alternative Brachytherapy Techniques for Early Prostate Cancer

Massachusetts General Hospital3 sites in 1 country414 target enrollmentMarch 2002

ConditionsProstate Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Prostate Cancer
Sponsor: Massachusetts General Hospital
Enrollment: 414
Locations: 3
Primary Endpoint: To assess changes in generic and disease specific quality of life over time after treatment with brachytherapy for early prostate cancer
Last Updated: 16 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this research study is to assess outcomes of treatment for early prostate cancer. Current treatments for early (non-metastatic) cancer may cause long-term impairments in the patients quality of life. In this study we will compare the outcomes of patients treated with two alternative brachytherapy (seed implants) techniques using a series of questionnaires.

Detailed Description

Participants will be asked to complete a questionnaire about their health prior to treatment, at 1, 3 and 12 months after treatment and then once a year 4 more times.

Registry

clinicaltrials.gov

Start Date

March 2002

End Date

March 2011

Last Updated

16 years ago

Study Type

Observational

Sex

Male

Investigators

Sponsor

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

•Pathological diagnosis of an adenocarcinoma of the prostate
•18 years of age or older
•Prior choice of either standard brachytherapy or MRIGPB as primary treatment

Exclusion Criteria

•Prior primary therapy (surgery or external beam radiation) for prostate cancer
•Current hormone ablation therapy

Outcomes

Primary Outcomes

To assess changes in generic and disease specific quality of life over time after treatment with brachytherapy for early prostate cancer

Time Frame: 10 years

Secondary Outcomes

To compare these outcomes after two alternative brachytherapy techniques, standard ultrasound guided brachytherapy and MRI guided prostate brachytherapy (MRIGPB)(10 years)
To identify factors associated with specific adverse outcomes.(10 years)